Subscribe: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies
http://img.marketwire.com/rss/mwPBES.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced  announces  cancer  company  health  marketwired  nasdaq  new  pleased announce  rennova  results  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Equipment and Supplies

Marketwired - Equipment and Supplies



Marketwired - Equipment and Supplies



Last Build Date: Thu, 25 May 2017 09:44:38 EDT

Copyright: Copyright: (C) Marketwired
 



Rennova Health Names Michael Pollack Interim Chief Financial Officer

Thu, 25 May 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - May 25, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the appointment of Michael Pollack, CPA as Interim Chief Financial Officer. Mr. Pollack brings approximately 30 years of corporate finance, reporting and consulting experience to Rennova, working with publicly traded and privately held companies with a particular focus on healthcare. Since 2005 Mr. Pollack has been with KBL, LLP, a certified public accounting and business advisory firm, most recently serving as Partner-in-Charge of KBL's audit quality and control, and the Partner-in-Charge of KBL's Public Company (SEC) Practices Group.




Pharmaceutical Case Studies Illustrating Data Analytics Strategies: New Webinar Hosted by Xtalks

Thu, 25 May 2017 07:30:00 EDT

Extracting the Most Value from Your Data Assets




Uncover Pharmacovigilance Insights with Data Discovery and Active Surveillance, New Webinar Hosted by Xtalks

Thu, 25 May 2017 07:00:00 EDT

Third in the series Four Steps to Shorten Your Clinical Trials with Informatics




Revive Therapeutics Ltd. Announces Results for the Three and Nine Months Ended March 31, 2017

Thu, 25 May 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - May 25, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF) announced today its results for the three and nine months ended March 31, 2017. The unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the period may be viewed on SEDAR at www.sedar.com.




Chinese OEMs Qualify LFS Scintillation Crystals for use in Positron Emission Tomography Medical Scanning Devices

Thu, 25 May 2017 03:15:00 EDT

SINGAPORE--(Marketwired - May 25, 2017) - Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I) (OTC PINK: ZMSPF), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that two additional Chinese, tier 1 positron emission tomography (PET) OEM integrators have successfully tested and qualified its patented LFS scintillation crystals for use in their current product lines of PET medical scanners.




Bio-Rad Introduces Enhanced Options with its IH-Com Data Management Software for Managing Patient Results with the IH-1000 System

Wed, 24 May 2017 16:15:00 EDT

HERCULES, CA--(Marketwired - May 24, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb), a global provider of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for enhanced capability with its IH-Com data management software to manage patient results with the company's IH-1000 automated blood typing instrument.




UPDATE - CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

Wed, 24 May 2017 15:42:29 EDT

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC--(Marketwired - May 24, 2017) - CROS NT today announced the go-live of its RaveX team in an extension of the company's partnership with Medidata.




KBI Biopharma selects The Windshire Group's and Simplyfeye's ProcessPad(TM) continued process verification solution

Wed, 24 May 2017 12:33:58 EDT

BOSTON, MA--(Marketwired - May 24, 2017) - The Windshire Group, LLC and Simplyfeye Inc. are pleased to announce KBI Biopharma, Inc. will deploy ProcessPadtm for its data analysis, management and reporting solution for process development, product scale-up and commercial manufacturing operations. KBI is a leading CDMO (contract development and manufacturing organization) and has served over 250 clients worldwide, including most of the top ten pharmaceutical companies.




CORRECTION - Cosmos Holdings, Inc. Announces first Quarter 2017 Results

Wed, 24 May 2017 11:40:00 EDT

CHICAGO, IL--(Marketwired - May 24, 2017) - In the news release, "Cosmos Holdings, Inc. Announces first Quarter 2017 Results," issued yesterday, May 23, by Cosmos Holdings (OTCQB: COSM), we are advised by the company that the subhead should read "Revenue Improved 262% and Gross Profit Improved 315% compared to the three months ended March 31, 2016." The "revenue improved" and "gross profit" percentages in the second paragraph were also updated. Complete corrected text follows.




Ovation Receives $1.5M in Funding and Launches Collaboration with iGeneTRAiN

Wed, 24 May 2017 08:57:06 EDT

CAMBRIDGE, MA--(Marketwired - May 24, 2017) -  Ovation Life Sciences, LLC (Ovation) announced today the receipt of 1.5 million dollars in funding from StageDotO, and existing investors, including Longfellow Ventures. The company will use the funds to continue the development of its next-generation scientific data-layer-as-a-service platforms, built to accelerate the progress of life science by improving how the story of scientific data is told. Ovation also announced a partnership with iGeneTRAiN to use Ovation Research to maximize collaboration capabilities across iGeneTRAiN's transplant consortium. The announcement was made today at the 2017 BioIT World Conference and Expo, www.bio-itworldexpo.com.




Rennova Health Reports First Quarter 2017 Financial Results

Wed, 24 May 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - May 24, 2017) - Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAZ) ("Rennova" or the "Company") reports financial results for the first quarter ended March 31, 2017 and provides a business update.




How to Upgrade Kombucha and Functional Beverage, Food, Supplement Products with Symbiotic Botanical Fermentation, New Webinar Hosted by Xtalks

Wed, 24 May 2017 08:18:30 EDT

TORONTO, ON--(Marketwired - May 24, 2017) - During a live broadcast, industry expert Chantale Houle, President of Kefiplant, will discuss the upcoming market opportunities for kombucha and botanicals.




The Good, the Bad, the Necessary in Rare Disease Studies, New Webinar Hosted by Xtalks

Wed, 24 May 2017 08:10:14 EDT

Live session on June 8, 2017 features expert panel from INC Research discussing the why, where, when and how a rare disease drug is intended to be used subsequent to approval and the importance of beginning with the end in mind




Nabsys Demonstrates High-Definition Whole Genome Mapping Performance Capturing Structural Variants in Microbial and Human Genomes, Plans Beta Program

Wed, 24 May 2017 08:01:00 EDT

Talks and Papers Previewed at PMWC 2017 and SFAF Conferences Advance Nabsys' Mission to Democratize Structural Information




Amfil Technologies Inc. Announces That Our Snakes & Lattes Inc. Subsidiary Is Finalizing a $1.25 Million CAD Purchase Order for a Popular Game Title That We Hold the Exclusive Distribution Rights to Canada, Partial Shipments on the Total Order Have Begun

Wed, 24 May 2017 08:00:00 EDT

TORONTO, ON--(Marketwired - May 24, 2017) - Amfil Technologies Inc. (OTC PINK: AMFE) is pleased to announce that our Snakes & Lattes Inc. subsidiary is in the final process of closing a purchase order with a large name-brand box store to sell approx. 50,000 units of a single title we hold exclusive distribution rights to in Canada. Partial shipments towards the total order have begun. It is estimated that Amfil Technologies Inc. will realize an approximate total revenue of $1.25 million CAD from this one purchaser for this one specific game title. 




SANUWAVE Health Announces Shock Wave Scientific Program in Milan, Italy Conducted by Medical Advanced Technologies, 26 May, 2017

Tue, 23 May 2017 15:00:00 EDT

SUWANEE, GA--(Marketwired - May 23, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company's exclusive distributor in Italy, Medical Advanced Technologies S.R.L. (MATEK) is sponsoring a one day scientific program to be conducted in Milan, Italy on May 26, 2017. This program, Workshop@Rooftop, will be held at the exclusive Hotel The Square in Milan. MATEK has been one of SANUWAVE's most active partners in promoting both dermaPACE® and orthoPACE® in Europe. Their innovative and proactive approach towards promoting dermaPACE and orthoPACE is reflected in this program which will assemble some of the most accomplished medical researchers and medical practitioners in Italy. The program will discuss the newest clinical information related to the mechanism of action for SANUWAVE's product line and to discuss clinical case-studies and on-going research in the field of extracorporeal shock wave technology (ESWT) and in particular the use of dermaPACE for wound indications and orthoPACE for orthopedic indications. Specific topics include:




Cosmos Holdings, Inc. Announces first Quarter 2017 Results

Tue, 23 May 2017 12:28:12 EDT

Revenue Improved 362% and Gross Profit Improved 415% compared to the three months ended March 31, 2016




Science Exchange Invited to Speak at the Novartis Institutes for Biomedical Research (NIBR) Seminar

Tue, 23 May 2017 12:00:00 EDT

Elizabeth Iorns, Ph.D., Founder and CEO of Science Exchange will present the Reproducibility Project: Cancer Biology




Protext Mobility Completes Name Change to Protext Pharma and Provides Update on Medical Cannabis License

Tue, 23 May 2017 10:00:00 EDT

BOCA RATON, FL--(Marketwired - May 23, 2017) - Protext Pharma, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical applications with highly bioavailable Phytofare® extracts, has announced today that its name change to Protext Pharma, Inc is now effective with the State of Delaware, and is pleased to provide the following shareholders update on its wholly owned subsidiary Cannabis Biosciences. The Company expects to submit the name change to FINRA in the coming days.




Vitargent introduces world's first product safety information platform applying proprietary Testing 2.0 biological testing technology

Tue, 23 May 2017 09:00:00 EDT

Safety of 100-plus edible oils thoroughly examined in breakthrough test




SinglePoint Continues Acquisition Strategy with New LOI -- CFN Media

Tue, 23 May 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - May 23, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article that covers SinglePoint Inc.'s (OTC PINK: SING) recently announced letter of intent with Discount Indoor Garden Supply.




ABcann's Pesticide-Free Approach is a Breath of Fresh Air -- CFN Media

Tue, 23 May 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - May 23, 2017) - CFN Media Group ("CFN Media"), the leading agency and digital media network dedicated to legal cannabis, today announced publication of an article covering ABcann Global Corp. (TSX VENTURE: ABCN) and why its pesticide-free approach sets a gold standard for the industry.




Nutra Pharma Announces Collaboration with the International Security Group for Development of Nerve Agent Counter Measures

Tue, 23 May 2017 08:30:00 EDT

CORAL SPRINGS, FL--(Marketwired - May 23, 2017) - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-AwayT in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a collaboration today with International Security Group to develop its nerve agent counter measures.




CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

Tue, 23 May 2017 08:30:00 EDT

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC--(Marketwired - May 23, 2017) - CROS NT today announced the go-live of its RaveX team in an extension of the company's partnership with Medidata.




BDS Evolves: New Website Launch Offers Options for Interaction

Tue, 23 May 2017 08:00:00 EDT

NEWBERG, OR--(Marketwired - May 23, 2017) - BDS is proud to announce the launch of their new website and social media platform. BDS' goal is to invite widespread participation and community building around their brand, and to offer customers even more opportunity for interaction. "BDS is very customer service oriented. It's great that you can get someone on the phone to discuss the products," states Craig M. Johnson, DMD, of Louisville KY. "They have a really good selection of high quality and affordable products."




REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India

Tue, 23 May 2017 07:59:17 EDT

Joint venture provides quality source of clinically annotated tissue specimens from vast Indian population




Does Weather Impact Performance or Reduce Capacity of Your Spray Dryers? New Food Industry Webinar Hosted by Xtalks

Tue, 23 May 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - May 23, 2017) - During a live broadcast on June 7, 2017, Bente Nielsen, Industry Manager of Global Food Industry at Munters A/S, will explain how food manufacturers can overcome climate related challenges by using air dehumidifiers in spray drying operations. The discussion will provide examples of how dehumidifiers have helped producers in the food industry experience the benefits of modern desiccant dehumidifiers, including producers of infant formula and different food ingredients.




Moleculin Biotech Issues Shareholder Update on FDA Designation of Orphan Drug and IND Status for Annamycin

Tue, 23 May 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - May 23, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center ("MD Anderson"), today announced that it has issued the following letter to its shareholders.




Self-Administration Injection Systems -- A Change in Market Trends Requires a Rethinking of Your Compounds Packaging, New Xtalks Webinar

Tue, 23 May 2017 07:00:00 EDT

Session will offer insight on the advantages of prefilled syringes and cartridges, including the various differentiators of the most commonly used syringe platforms -- pre-sterilized and bulk




Zecotek Delivers Patented LFS Scintillation Crystals to Multiple High Tech Institutions

Tue, 23 May 2017 03:15:00 EDT

SINGAPORE--(Marketwired - May 23, 2017) - Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I)(OTC PINK: ZMSPF),a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that four prestigious high tech institutions have ordered its patented LFS scintillation crystals for both medical imaging and high energy physics experiments.




Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors

Mon, 22 May 2017 16:32:41 EDT

BOSTON, MA--(Marketwired - May 22, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has joined the Company's Board of Directors, bringing the total number of directors to eight.




Three Ogilvy CommonHealth Worldwide executives to speak at the 2017 e-RX and EHR Conference

Mon, 22 May 2017 15:26:51 EDT

PARSIPPANY, NJ--(Marketwired - May 22, 2017) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced Angelo Campano, Russell Grimaldi, and Ritesh Patel will present at the 2017 e-RX and EHR Conference on May 23-24, 2017, in Philadelphia, PA.




MyDx Reports First Quarter Results

Mon, 22 May 2017 09:58:42 EDT

Strong Performance of CannaDx Drives Sales Growth, Leading To Positive Cash-Flow Generation




MySize Targets Growth Opportunities in Europe - SECFilings.com

Mon, 22 May 2017 09:00:00 EDT

REDONDO BEACH, CA--(Marketwired - May 22, 2017) -  SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces the publication of an article discussing MySize Inc. (NASDAQ: MYSZ) (TASE: MYSZ) and its focus on Europe for growth potential.




Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017

Mon, 22 May 2017 07:57:00 EDT

FRAMINGHAM, MA--(Marketwired - May 22, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the LD Micro Invitational, which will take place from June 6-7, 2017 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.




Innovus Makes Strides Toward Goal of Tripling Revenue in 2017 -- SECFilings.com

Fri, 19 May 2017 09:00:00 EDT

REDONDO BEACH, CA--(Marketwired - May 19, 2017) -  SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article discussing Innovus Pharmaceuticals' (OTCQB: INNV) recent financial results and the company's goals going forward.




Propanc Biopharma Highlights PRP's Potential to Reprogram Cancer Stem Cells (CSCs)

Fri, 19 May 2017 08:30:00 EDT

MELBOURNE, AUSTRALIA--(Marketwired - May 19, 2017) - Propanc Biopharma Inc. (OTCQB: PPCH) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that fresh new insights have emerged into how cancer stem cells (CSCs) are able to resist standard treatments, become more aggressive and spread rapidly. Published in Oncogene, by researchers from the Bellvitge Biomedical Research Institute south of Barcelona, Spain, the findings have significant implications for Propanc Biopharma's lead product PRP, which reprograms CSCs so that they are no longer malignant and a threat to the patient. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.




Lion Biotechnologies Announces First Patient Dosed in Second Cohort of LN-144 Phase 2 Trial for Metastatic Melanoma

Fri, 19 May 2017 08:01:00 EDT

SAN CARLOS, CA--(Marketwired - May 19, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in the second cohort of its ongoing Phase 2 trial of LN-144 for the treatment of patients with metastatic melanoma. This cohort utilizes the company's generation 2 manufacturing process which includes cryopreservation of the outbound products.




Atossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study

Fri, 19 May 2017 08:00:00 EDT

SEATTLE, WA--(Marketwired - May 19, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it completed enrollment in the topical arm of its Phase 1 dose escalation study of Atossa's proprietary Endoxifen. Endoxifen is an active metabolite of the FDA-approved drug tamoxifen, which is used to treat breast cancer and for breast cancer prevention in high risk patients. 




Using Early Economic Models in Developing your Evidence Strategy

Fri, 19 May 2017 07:30:00 EDT

The demand from regulators and payers for health economic models is increasing, as these key decision makers struggle to manage budget constraints and provide access to new therapies




Relevium Provides Update on Financing and Acquistion of BioGanix

Thu, 18 May 2017 18:25:40 EDT

MONTREAL, QUEBEC--(Marketwired - May 18, 2017) - Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the "Company" or "Relevium") a consolidator of e-commerce assets in Health and Wellness is pleased to provide an update on the acquisition of BioGanix and the related financing.




Valens GroWorks Announces Receipt of Dealer's Licence

Thu, 18 May 2017 17:40:09 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 18, 2017) - Valens GroWorks Corp. (CSE:VGW)(CSE:VGW.CN)(CNSX:VGW) (the "Company" or "Valens") is pleased to announce Valens Agritech Ltd. ("VAL"), a wholly owned subsidiary of the Company, has received a Dealer's Licence pursuant to the provisions of the Controlled Drugs and Substances Act and its Regulations and will now begin operations. The issuance of the licence follows an extensive multi-year process that included application, design, construction and security clearance of key personnel.




Rennova Health Postpones Special Meeting of Stockholders to May 26, 2017

Thu, 18 May 2017 16:15:00 EDT

WEST PALM BEACH, FL--(Marketwired - May 18, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the postponement of its Special Meeting of stockholders that was to have taken place on May 19, 2017. The postponement is necessary to achieve a quorum of shares represented at the meeting. The new date for the Special Meeting is May 26, 2017 at 11:00 a.m. Eastern time and it will take place at the offices of Shutts & Bowen LLP, 525 Okeechobee Boulevard, Suite 1100, West Palm Beach, FL 33401. The record date of April 21, 2017 remains unchanged.




Nutritional High Provides Update on Operations in Pueblo, Colorado

Thu, 18 May 2017 13:28:51 EDT

TORONTO, ONTARIO--(Marketwired - May 18, 2017) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(CSE:EAT.CN)(CNSX:EAT)(OTCQB:SPLIF)(FRANKFURT:2NU) is pleased to announce an update on operations in Pueblo, CO.




Rigado Named a 2017 Cool Vendor in the Internet of Things

Thu, 18 May 2017 12:20:11 EDT

Rigado recognized as a Cool Vendor for its IoT gateway and integrated wireless platform




True Nature Announces Targeted Community Health Initiative

Thu, 18 May 2017 11:26:01 EDT

ATLANTA, GA--(Marketwired - May 18, 2017) -  True Nature Holding, Inc. (OTCQB: TNTY) (the "Company") today announced that it is rolling out a new initiative aimed supporting the need for lower cost pharmaceuticals within the medically underserved small town and rural marketplaces. The Company intends to form a joint venture for-profit subsidiary; True Nature Community Health, Inc., which will be owned 51% percent by the public company, and 49% by a newly formed not-for-profit entity; The True Nature Community Health Foundation.